Evidence map›Paper›PMID 35429101›Full record

ArticleJournal of cellular and molecular medicine2022

Sodium butyrate inhibits aerobic glycolysis of hepatocellular carcinoma cells via the c-myc/hexokinase 2 pathway.

Qiang Yu, Weiqi Dai, Jie Ji, Liwei Wu, Jiao Feng, Jingjing Li, Yuanyuan Zheng, Yan Li, Ziqi Cheng, Jie Zhang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Gut-Derived Sodium Butyrate Attenuates Liver Fibrosis by Inhibiting Aerobic Glycolysis via the HDAC3/c-Myc Signaling Axis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. The Knockdown of USP34 Inhibits the Progression of Hepatocellular Carcinoma by Accelerating c-Myc Degradation.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
    Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Qiang YuDepartment of Gastroenterology, Shanghai Tenth People's Hospital, School of medicine, Tongji University, 200072, Shanghai, China.
Weiqi DaiDepartment of Gastroenterology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, 200433, Shanghai, P.R.China.
Jie JiDepartment of Gastroenterology, Shanghai Tenth People's Hospital, School of medicine, Tongji University, 200072, Shanghai, China.
Liwei WuDepartment of Gastroenterology, Shanghai Tenth People's Hospital, School of medicine, Tongji University, 200072, Shanghai, China.
Jiao FengDepartment of Gastroenterology, Shanghai Tenth People's Hospital, School of medicine, Tongji University, 200072, Shanghai, China.
Jingjing LiDepartment of Gastroenterology, Shanghai Tenth People's Hospital, School of medicine, Tongji University, 200072, Shanghai, China.
Yuanyuan ZhengDepartment of Gastroenterology, Shanghai Tenth People's Hospital, School of medicine, Tongji University, 200072, Shanghai, China.
Yan LiDepartment of Gastroenterology, Shanghai Tenth People's Hospital, School of medicine, Tongji University, 200072, Shanghai, China.
Ziqi ChengDepartment of Gastroenterology, Shanghai Tenth People's Hospital, School of medicine, Tongji University, 200072, Shanghai, China.
Jie ZhangDepartment of Gastroenterology, Shanghai Tenth People's Hospital, School of medicine, Tongji University, 200072, Shanghai, China.
Jianye WuDepartment of Gastroenterology, Putuo People's Hospital, Tongji University, 200060, Shanghai, China.
Xuanfu XuDepartment of Gastroenterology, Shidong Hospital, Yangpu District, Shidong Hospital Affiliated to University of Shanghai for Science and Technology, 200433, Shanghai, P.R.China.
Chuanyong GuoDepartment of Gastroenterology, Shanghai Tenth People's Hospital, School of medicine, Tongji University, 200072, Shanghai, China.ORCID 0000-0002-6527-4673
Tongji University · CNUniversity of Shanghai for Science and Technology · CN

Funding

National Natural Science Foundation of China 82002539National Natural Science Foundation of China 82100638National Natural Science Foundation of China 82102956the Health System Innovation Project of Shanghai Putuo Science and Technology Commission PTKWWS201903the Yangfan Project of Shanghai Science and Technology Commission 20YF1443300the Yangfan Project of Shanghai Science and Technology Commission 21YF1435400
6 · The paper itself

Abstract

Aerobic glycolysis is a well-known hallmark of hepatocellular carcinoma (HCC). Hence, targeting the key enzymes of this pathway is considered a novel approach to HCC treatment. The effects of sodium butyrate (NaBu), a sodium salt of the short-chain fatty acid butyrate, on aerobic glycolysis in HCC cells and the underlying mechanism are unknown. In the present study, data obtained from cell lines with mouse xenograft model revealed that NaBu inhibited aerobic glycolysis in the HCC cells in vivo and in vitro. NaBu induced apoptosis while inhibiting the proliferation of the HCC cells in vivo and in vitro. Furthermore, the compound inhibited the release of lactate and glucose consumption in the HCC cells in vitro and inhibited the production of lactate in vivo. The modulatory effects of NaBu on glycolysis, proliferation and apoptosis were related to its modulation of hexokinase 2 (HK2). NaBu downregulated HK2 expression via c-myc signalling. The upregulation of glycolysis in the HCC cells induced by sorafenib was impeded by NaBu, thereby enhancing the anti-HCC effect of sorafenib in vitro and in vivo. Thus, NaBu inhibits the expression of HK2 to downregulate aerobic glycolysis and the proliferation of HCC cells and induces their apoptosis via the c-myc pathway.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnimalsButyric AcidCell LineCell Line, TumorCell ProliferationGlycolysisHexokinaseHumansLactatesMiceSorafenibButyric AcidHexokinaseLactatesSorafenibaerobic glycolysishepatocellular carcinomahexokinase 2sodium butyratesorafenib

Identifiers

PMID35429101
PMCPMC9097842
OpenAlexW4223896227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.